Aktis Oncology, Inc. (AKTS)
| Market Cap | 1.03B |
| Revenue (ttm) | 10.06M +576.5% |
| Net Income | -73.14M |
| EPS | -2.77 |
| Shares Out | 55.62M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 309,889 |
| Open | 18.75 |
| Previous Close | 18.52 |
| Day's Range | 17.93 - 18.82 |
| 52-Week Range | 14.72 - 34.19 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 35.39 (+91.09%) |
| Est. Earnings | Nov 12, 2026 |
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A... [Read more]
Financial Performance
In 2025, Aktis Oncology's revenue was $6.50 million, an increase of 336.92% compared to the previous year's $1.49 million. Losses were -$63.73 million, 44.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AKTS stock is "Strong Buy." The 12-month stock price target is $35.39, which is an increase of 91.09% from the latest price.
News
Aktis Oncology initiates second Phase 1b trial for AKY-2519
Aktis Oncology (AKTS) announced the initiation of the Phase 1b BActinium-2 trial of AKY-25191 in patients with NSCLC and other B7-H3 expressing solid tumor types. The BActinium-2 trial is part…
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
Phase 1b BActinium-2 clinical trial is evaluating AKY-2519 in patients with non-small cell lung cancer (NSCLC) and other B7-H3 expressing tumors Enrollment is ongoing in the Phase 1b BActinium-1 clini...
Aktis Oncology Slides: Corporate presentation
Aktis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on September 18, 2026.
Aktis Oncology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Radiopharmaceuticals are positioned as a transformative oncology modality, with a proprietary miniprotein platform enabling multi-tumor targeting and rapid clinical progress. Two lead programs, AKY-1189 (Nectin-4) and AKY-2519 (B7-H3), are advancing through phase I, supported by robust supply chain investments and a strong financial position.
Oppenheimer bullish on Aktis Oncology, initiates with an Outperform
As previously reported, Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target The firm’s thesis is driven by its enthusiasm for the company’s miniprote...
Aktis Oncology initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $40 price target
Wedbush starts Aktis Oncology at Outperform on radiopharma potential
Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target The firm views Aktis as “compelling pure-play radiopharma story targeting ...
Aktis Oncology initiated with an Outperform at Wedbush
Wedbush analyst David Nierengarten initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $35 price target
BMO starts Aktis at Outperform, says opportunities not captured in valuation
BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price target The firm said its Outperform thesis is underpinned by the significant…
Aktis Oncology initiated with an Outperform at BMO Capital
BMO Capital analyst David Lebowitz initiated coverage of Aktis Oncology (AKTS) with an Outperform rating and $37 price target BMO rolled out coverage on nine biotechnology companies, saying each might...
Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M
“This was a quarter of strong execution for Aktis, focused on generating clinical data and building infrastructure to support our clinical pipeline,” said Matthew Roden, President and Chief Executive ...
Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (“Aktis” or the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted r...
Aktis Oncology Earnings release: Q2 2026
Aktis Oncology released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Aktis Oncology Quarterly report: Q2 2026
Aktis Oncology has published its Q2 2026 quarterly earnings report on August 13, 2026.
Aktis Oncology price target raised to $33 from $30 at JPMorgan
JPMorgan raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps an Overweight rating on the shares. The firm upped the target after revisiting its…
Aktis Oncology initiated with a Strong Buy at Raymond James
Raymond James analyst Christopher Raymond initiated coverage of Aktis Oncology (AKTS) with a Strong Buy rating and $40 price target The firm thinks Aktis’ miniprotein-enabled radioligand therapy platf...
Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026
Aktis Oncology presented its strategy to expand radiopharmaceuticals to new patient groups using a proprietary mini-protein platform, with two lead assets in phase I-B trials targeting Nectin-4 and B7-H3. Robust early clinical data, strong financials, and a resilient supply chain support multi-indication development and upcoming milestones in 2027.
Aktis Oncology Slides: FY 2026
Aktis Oncology has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 3, 2026.
Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $35 from $33 and keeps a Buy rating on the shares after the company presented…
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Status update
AKY-2519, a B7-H3-targeting radiopharmaceutical, demonstrated robust tumor uptake, high tumor-to-normal tissue dose ratios, and favorable safety in early studies. Experts highlighted its potential to address unmet needs in prostate and other solid tumors, with clinical trials underway in multiple indications.
Aktis Oncology Slides: Status update
Aktis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.